Suggested remit - To appraise the clinical and cost-effectiveness of nivolumab with ipilimumab within its marketing authorisation for adjuvant treatment of completely resected stage III or IV melanoma
Following on from information provided to NICE by the company in December 2020, the appraisal of Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma [ID1610] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 1610

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
21 November 2022 Following on from information provided to NICE by the company in December 2020, the appraisal of Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma [ID1610] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
21 November 2022 Discontinued. Following on from information provided to NICE by the company in December 2020, the appraisal of Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma [ID1610] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
10 December 2020 The Department for Health and Social Care has asked NICE to carry out an appraisal of nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma For information, the company have announced that CheckMate -915 did not meet its primary endpoint and therefore they will no longer be pursuing a marketing authorisation application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes
10 December 2020 Suspended. Topic is suspended
13 September 2019 - 11 October 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
09 August 2019 In progress. Referred 31 July 2017

For further information on our processes and methods, please see our CHTE processes and methods manual